Malignancies, allergic reactions, and autoimmune-inflammatory manifestations occur with some frequency among patients with primary immunodeficiency diseases.
Malignancies, allergic reactions, and autoimmune-inflammatory manifestations occur with some frequency among patients with primary immunodeficiency diseases.
Patients with psoriatic arthritis who had not responded to or tolerated other therapies achieved significant improvements over 52 weeks when treated with risankizumab 150 mg.
Patients with psoriatic arthritis who had not responded to or tolerated other therapies achieved significant improvements over 52 weeks when treated with risankizumab 150 mg.
